MYCIO Wealth Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

MYCIO Wealth Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-700	Closed	-$65K	–	271
2016 Q3	$65K	Sell	700 -19	-3%	-$1.79K	0.01%	304
2016 Q2	$56K	Buy	719 +19	+3%	+$1.61K	0.01%	321
2016 Q1	$58K	Hold	700	–	–	0.01%	297
2015 Q4	$73K	Hold	700	–	–	0.01%	250
2015 Q3	$74K	Hold	700	–	–	0.02%	247
2015 Q2	$96K	Hold	700	–	–	0.02%	222
2015 Q1	$87K	Buy	+700	New	+$74.2K	0.02%	220

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MYCIO Wealth Partners's BMRN Position: Q4 2016 in Review

MYCIO Wealth Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2016, closing a stake of 700 shares — an estimated $65K sold.

MYCIO Wealth Partners first reported a position in BMRN in Q1 2015 and held it in 7 quarters. The position peaked at $96K in Q2 2015. 415 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

MYCIO Wealth Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
MYCIO Wealth Partners sold 700 BioMarin Pharmaceuticals shares in Q4 2016, an estimated $65K.
MYCIO Wealth Partners first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 7 quarters.
MYCIO Wealth Partners's BioMarin Pharmaceuticals position peaked at $96K in Q2 2015.
415 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on MYCIO Wealth Partners's 13F filing for Q4 2016, filed 1 Feb 2017.